Inventing New Medicines
Pioneering Targeted Protein Degradation
News & Events
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation SummitRead More
Kymera Therapeutics to Present at Upcoming September Investor ConferencesRead More
Targeted Protein Degradation
A New Way to Treat Disease
Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Kymera is driven to invent transformative medicines for a wide variety of diseases where traditional drug modalities have failed to sufficiently unlock the appropriate biological solution.
A Powerful Drug Discovery Engine
Kymera has developed a proprietary targeted protein degradation platform called Pegasus which enables the design of highly selective small molecule protein degraders – heterobifunctional molecules with potent activity against disease-causing proteins. Thanks to our Whole Body E3 Ligase Atlas, Pegasus is expanding the universe of potential disease targets and possible treatments.